Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03875313
Title Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Calithera Biosciences, Inc

colorectal cancer

clear cell renal cell carcinoma

triple-receptor negative breast cancer


Talazoparib + Telaglenastat

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.